Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Borsch

Interventional Cardiology Bristol, TN Medical Doctor

NPI 1447288667 CMS profile 156025

1 Medical Park Blvd, Suite 458W, Bristol, TN 37620

Open in the dashboard

General payments

$16,257

592 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Borsch of Bristol, TN is reported in the CMS Open Payments database as having received $16,257 across 592 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,692 84
2024 General $2,762 110
2023 General $2,104 87
2022 General $2,962 91
2021 General $2,308 81
2020 General $1,898 59
2019 General $1,532 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Borsch
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Mark Borsch were reported at $2,692. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Mark Borsch Interventional Cardiology median Middle half National median
2019 $1,532 $1,097 $329–$3,048 $163
2020 $1,898 $473 $161–$1,480 $114
2021 $2,308 $677 $233–$1,827 $132
2022 $2,962 $978 $333–$2,724 $149
2023 $2,104 $1,136 $382–$2,986 $160
2024 $2,762 $1,181 $395–$3,326 $164
2025 $2,692 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $4,716 140 payments
  2. Novartis Pharmaceuticals Corporation $2,777 154 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,048 32 payments
  4. Cardiovascular Systems Inc. $1,013 17 payments
  5. Abiomed $945 17 payments
  6. Janssen Pharmaceuticals, Inc $798 33 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $550 18 payments
  8. Philips Electronics North America Corporation $532 16 payments
  9. Amgen Inc. $394 21 payments
  10. AstraZeneca Pharmaceuticals LP $373 17 payments
  11. Other $3,112 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,553 589 payments
  2. Travel and Lodging $696 2 payments
  3. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. ENTRESTO $1,125 68 payments
  2. LifeVest $1,048 32 payments
  3. LEQVIO $1,024 49 payments
  4. Xience Skypoint $922 49 payments
  5. Coronary Orbital Atherectomy System $908 11 payments
  6. Impella $858 16 payments
  7. XARELTO $798 33 payments
  8. DRAGONFLY OPSTAR $577 10 payments
  9. JARDIANCE $550 18 payments
  10. ULTREON $435 9 payments
  11. Other $8,637 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

3,151

Median for Interventional Cardiology: 2,236

Drug cost

$459,822

Median for Interventional Cardiology: $380,412

Branded share of claims

33.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 220 $222,707
Entresto Sacubitril/Valsartan Brand 60 $68,873
Xarelto Rivaroxaban Brand 94 $63,879
Brilinta Ticagrelor Brand 41 $29,730
Jardiance Empagliflozin Brand 25 $21,597
Repatha Sureclick Evolocumab Brand 15 $8,198
Repatha Syringe Evolocumab Brand 12 $6,284
Ranolazine Er Ranolazine Brand 78 $5,842
Bisoprolol Fumarate Generic 212 $4,781
Vascepa Icosapent Ethyl Brand 11 $4,050

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$45,572

Medicare's payments for the services billed

Medicare patients

609

Average age 75

Services billed

975

305 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 42%
Diabetes 41%
Atrial fibrillation 41%
Heart failure 34%
Chronic kidney disease 34%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $298
$298 — —
Repatha
  • Amgen Inc. $111
$111 27 —
INJECTAFER
  • Daiichi Sankyo Inc. $51
$51 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $44
$44 60 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

592 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record